ReachMD CME

CME credits: 0.75 Valid until: 28-04-2027 Claim your CME credit at https://reachmd.com/programs/cme/tau-therapies-and-clinical-translation-mechanistic-approaches/56762/ This series of brief episodes examines Alzheimer’s disease (AD) as an integrated neurodegenerative and neuropsychiatric syndrome. Drs. Marwan Sabbagh and Dani Cabral highlight challenges in clinical phenotyping and the consequences...

CME credits: 0.75 Valid until: 28-04-2027 Claim your CME credit at https://reachmd.com/programs/cme/Amyloid-Therapies-in-Practice-Not-All-Are-Created-Equal/56761/ This series of brief episodes examines Alzheimer’s disease (AD) as an integrated neurodegenerative and neuropsychiatric syndrome. Drs. Marwan Sabbagh and Dani Cabral highlight challenges in clinical phenotyping and the consequences of tr...

CME credits: 1.00 Valid until: 15-04-2027 Claim your CME credit at https://reachmd.com/programs/cme/Key-Takeaways-and-Practice-Integration/56710/ Demodex blepharitis (DB) is a common yet frequently underrecognized condition, often misdiagnosed as dry eye disease or meibomian gland dysfunction, leading to delayed treatment and increased patient burden. Clinicians need improved recognition of hallma...

CME credits: 1.00 Valid until: 15-04-2027 Claim your CME credit at https://reachmd.com/programs/cme/return-and-revisit-a-38-year-old-patient-returns-for-follow-up-after-lotilaner-treatment/56709/ Demodex blepharitis (DB) is a common yet frequently underrecognized condition, often misdiagnosed as dry eye disease or meibomian gland dysfunction, leading to delayed treatment and increased patient burd...

CME credits: 1.00 Valid until: 15-04-2027 Claim your CME credit at https://reachmd.com/programs/cme/closing-the-loop-structured-follow-up-and-patient-communication/56708/ Demodex blepharitis (DB) is a common yet frequently underrecognized condition, often misdiagnosed as dry eye disease or meibomian gland dysfunction, leading to delayed treatment and increased patient burden. Clinicians need impro...

CME credits: 1.00 Valid until: 15-04-2027 Claim your CME credit at https://reachmd.com/programs/cme/the-neverending-journey-a-66-year-old-patient-who-has-undergone-several-rounds-of-tea-tree-oilbased-treatment/56707/ Demodex blepharitis (DB) is a common yet frequently underrecognized condition, often misdiagnosed as dry eye disease or meibomian gland dysfunction, leading to delayed treatment and i...

CME credits: 1.00 Valid until: 15-04-2027 Claim your CME credit at https://reachmd.com/programs/cme/moving-beyond-lid-hygiene-evidence-based-treatment-strategies/56706/ Demodex blepharitis (DB) is a common yet frequently underrecognized condition, often misdiagnosed as dry eye disease or meibomian gland dysfunction, leading to delayed treatment and increased patient burden. Clinicians need improve...

CME credits: 1.00 Valid until: 15-04-2027 Claim your CME credit at https://reachmd.com/programs/cme/the-missed-diagnosis-a-45-year-old-software-engineer-who-complains-of-dry-eyes/56705/ Demodex blepharitis (DB) is a common yet frequently underrecognized condition, often misdiagnosed as dry eye disease or meibomian gland dysfunction, leading to delayed treatment and increased patient burden. Clinic...

CME credits: 1.00 Valid until: 15-04-2027 Claim your CME credit at https://reachmd.com/programs/cme/At-the-Intersection-of-DB-DED-MGD-and-Other-Forms-of-Blepharitis/56704/ Demodex blepharitis (DB) is a common yet frequently underrecognized condition, often misdiagnosed as dry eye disease or meibomian gland dysfunction, leading to delayed treatment and increased patient burden. Clinicians need impr...

CME credits: 1.00 Valid until: 15-04-2027 Claim your CME credit at https://reachmd.com/programs/cme/Catching-Demodex-in-the-Act/56703/ Demodex blepharitis (DB) is a common yet frequently underrecognized condition, often misdiagnosed as dry eye disease or meibomian gland dysfunction, leading to delayed treatment and increased patient burden. Clinicians need improved recognition of hallmark signs su...

CME credits: 0.25 Valid until: 24-04-2027 Claim your CME credit at https://reachmd.com/programs/cme/living-with-systemic-mastocytosis-bridging-clinical-decisions-and-patient-realities/54389/ This online CME activity explores the clinical complexity and real-world impact of systemic mastocytosis through both clinician insight and patient experience. Participants will examine the multisystem burden...

CME credits: 1.00 Valid until: 23-04-2027 Claim your CME credit at https://reachmd.com/programs/cme/precision-strikes-in-aml-navigating-the-evolving-landscape-of-targeted-therapies/48856/ This educational series explores evolving strategies in the management of acute myeloid leukemia (AML) with a focus on targeted therapies. Faculty experts will review molecular diagnostics and guideline-driven us...

CME credits: 1.00 Valid until: 20-04-2027 Claim your CME credit at https://reachmd.com/programs/cme/grooving-through-lipid-management-a-new-rhythm-in-ascvd-risk-reduction/57097/ On-demand webcast covering the latest advances in lipid management and atherosclerotic cardiovascular disease risk reduction, including the emerging role of lipoprotein(a), data on novel lipid-lowering therapies, and strat...

CME credits: 1.00 Valid until: 20-04-2027 Claim your CME credit at https://reachmd.com/programs/cme/hidden-in-plain-sight-a-modern-guide-to-detecting-and-managing-early-neurotrophic-keratitis/54091/ Neurotrophic keratitis (NK) remains significantly underdiagnosed because early findings are easily mistaken for dry eye disease and other ocular surface disorders. Although reduced corneal sensitivity...

CME credits: 1.00 Valid until: 20-04-2027 Claim your CME credit at https://reachmd.com/programs/cme/beyond-iop-integrating-ocular-surface-resilience-into-glaucoma-management/49097/ Glaucoma care is shifting from a narrow focus on pressure targets to a broader, patient-centered approach that balances durable intraocular pressure (IOP) control with preservation of the ocular surface, comfort, and re...

CME credits: 0.50 Valid until: 15-04-2027 Claim your CME credit at https://reachmd.com/programs/cme/retina-rumble-debating-modern-treatment-options/54609/ Current guidelines recommend the use of second-generation therapies for the treatment of retinal diseases; however, limited head-to-head study data make it difficult to determine which strategies to use for specific patients and at what time. In...

CME credits: 1.00 Valid until: 10-04-2027 Claim your CME credit at https://reachmd.com/programs/cme/enhancing-collaborative-care-in-retinal-diseases-a-focus-on-injection-therapies/37715/ This rebroadcast of a live regional meeting series, part of The Focused Sight Initiative: Quality Improvement Interventions in Retinal Diseases, brings together retina specialists and eye care professionals to add...

CME credits: 1.50 Valid until: 08-04-2027 Claim your CME credit at https://reachmd.com/programs/cme/experts-master-class-diagnosis-treatment-advances-hidradenitis-suppurativa/56410/ On-demand webcast on the pathophysiology of hidradenitis suppurativa (HS), best practices for its timely diagnosis and long-term management, and the latest data on emerging therapies. =

CME credits: 0.25 Valid until: 08-04-2027 Claim your CME credit at https://reachmd.com/programs/cme/cgm-full-potential-t2d/50980/ Continuous glucose monitoring (CGM) has been widely used in individuals with type 1 diabetes (T1D), and evolving guidelines increasingly recommend its use for those with type 2 diabetes (T2D) as well. However, despite these updated recommendations, real-world adoption t...

CME credits: 0.25 Valid until: 07-04-2027 Claim your CME credit at https://reachmd.com/programs/cme/transforming-care-in-pediatric-patients-with-c3-glomerulopathy-targeting-c3-at-the-source/54143/ Complement-mediated kidney diseases such as C3 glomerulopathy (C3G) continue to present significant diagnostic and therapeutic challenges in nephrology for both adult and pediatric patients. Among childr...

CME credits: 1.50 Valid until: 05-04-2027 Claim your CME credit at https://reachmd.com/programs/cme/cardio-renal-metabolic-care-evidence-based-therapies-optimize-outcomes/56917/ On-demand webcast on best practices for optimizing guideline-directed medical therapy in cardiovascular-renal-metabolic (CRM) care and employing SGLT2 inhibitors to treat patients with CRM conditions, including heart failu...

CME credits: 0.25 Valid until: 02-04-2027 Claim your CME credit at https://reachmd.com/programs/cme/The-Future-of-HNSCC-Aligning-Teams-Transforming-Care/54394/ This activity reviews data from the KEYNOTE-689 and NIVOPOSTOP trials evaluating perioperative immune checkpoint inhibition in resectable, locally advanced head and neck squamous cell carcinoma (HNSCC). Experts examine trial design, efficac...

CME credits: 0.25 Valid until: 31-03-2027 Claim your CME credit at https://reachmd.com/programs/cme/navigating-today-and-shaping-tomorrow-in-ism-personalized-strategies-with-current-and-emerging-kit-inhibitors/54388/ This online educational activity explores the evolving role of KIT-targeted tyrosine kinase inhibitors (TKIs) in indolent systemic mastocytosis (ISM). Expert faculty discuss pivotal c...

CME credits: 0.25 Valid until: 31-03-2027 Claim your CME credit at https://reachmd.com/programs/cme/stuck-on-antihistamines-for-managing-patients-with-ckd-ap-time-to-reconsider/37607/ Despite effective and recommended therapies, many healthcare providers still consider antihistamines as the first-choice treatment for CKD-associated pruritus. Join Drs. Antoine Lanot and Gil Yosipovitch as they revi...

CME credits: 1.00 Valid until: 19-05-2027 Claim your CME credit at https://reachmd.com/programs/cme/modern-obstructive-hcm-care-from-unmet-needs-to-individualized-myosin-inhibitor-therapy/56979/ This activity examines the evolving management of obstructive hypertrophic cardiomyopathy (oHCM), from persistent unmet needs to precision-based therapy with cardiac myosin inhibitors. Faculty review ongoi...